Dr Schüttrumpf also discusses emerging platforms such as recombinant polyclonal therapeutics, as well as the integration of ...

Lilly has seen dramatic sales growth over the last couple of years from its injectable, dual GLP-1/GIP agonist obesity ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue ...

Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57 ...

NHS England has said that the new online hospital, due to launch next year, will focus initially on nine common conditions, ...

The number of immunisations universally recommended for all children has fallen from 17 to 11, with six of them now ...

At a time when patients demand greater transparency and control over their health journey, patient engagement is no longer a ...

The Danish drugmaker said the drug will be available from today at prices starting from $149 per month for cash purchasers.

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...